Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) 3-Year EBITDA Growth Rate : -15.60% (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 3-Year EBITDA Growth Rate?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was HK$0.00.

During the past 12 months, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's average EBITDA Per Share Growth Rate was -59.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -15.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -5.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co was 36.30% per year. The lowest was -15.60% per year. And the median was 13.45% per year.

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (HKSE:01349) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

688505:China

Address

No. 308, Cai Lun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210

Website

http://www.fd-zj.com

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Headlines

No Headlines